Lauren V. Wood, M.D.
Dr. Wood joined PDS Biotechnology as Chief Medical Officer in February 2019. She has overall responsibility for clinical development of the novel, immune activating Verrsamune® platform product pipeline targeting HPV-related pre-cancer and advanced cancers as well as a broad spectrum of solid tumors. With 30 years of extensive clinical research experience at the National Institutes of Health, Dr. Wood most recently was the Clinical Director of the Vaccine Branch, Center for Cancer Research, National Cancer Institute. While there she oversaw the translational development of immune-based therapies for both cancer and HIV infection and was a co-inventor of two patented therapeutic cancer vaccine platforms targeting the TARP and HER tumor antigens. Prior to joining the Vaccine Branch, Dr. Wood was a Senior Clinical Investigator from 1992-2009 in the NCI Pediatric Oncology and HIV and AIDS Malignancy Branches, overseeing teams investigating antiretroviral, anti-infective, and immunomodulatory therapies for HIV-infected children, adolescents and young adults. Trained in both Internal Medicine and Pediatrics with subspecialty training in Allergy and Immunology from NIAID, Dr. Wood received her M.D. from Duke University School of Medicine and B.A. in Biology from Oberlin College.